


TA-02

Cat. No.:	HY-100115		
CAS No.:	1784751-19-4		
Molecular Formula:	C ₂₀ H ₁₃ F ₂ N ₃		
Molecular Weight:	333.33		
Target:	p38 MAPK; Autophagy		
Pathway:	MAPK/ERK Pathway; Autophagy		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (75.00 mM; Need ultrasonic)
 H₂O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.0000 mL	15.0002 mL	30.0003 mL
	5 mM	0.6000 mL	3.0000 mL	6.0001 mL
	10 mM	0.3000 mL	1.5000 mL	3.0000 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (7.50 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (7.50 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

TA-02 is a p38 MAPK inhibitor with IC₅₀ of 20 nM. IC₅₀ value: 20 nM. Target: p38. TA-02 is a novel compound with similar cardiogenic properties as SB203580 and SB202190. TA-02 especially inhibits TGFBR-2.

CUSTOMER VALIDATION

-
- **Exp Ther Med.** 2019 Mar;17(3):1688-1696.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Laco F, et al. Cardiomyocyte differentiation of pluripotent stem cells with SB203580 analogues correlates with Wnt pathway CK1 inhibition independent of p38 MAPK signaling. *J Mol Cell Cardiol.* 2015 Mar;80:56-70.
- [2]. Filip LACO, et al. 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis. WO 2015119579 A1.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA